CLINICAL TRIALS PROFILE FOR LOXAPINE SUCCINATE
✉ Email this page to a colleague
All Clinical Trials for LOXAPINE SUCCINATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00648778 ↗ | Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | The objective of this study was to investigate the bioequivalence of Mylan loxapine succinate 25 mg capsules to Watson Loxitane 25 mg capsules following a single, oral 25 mg (1 x 25 mg) dose administration under fasting conditions. |
NCT02820519 ↗ | Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain | Terminated | University of Witten/Herdecke | Phase 2 | 2016-06-01 | Loxapine is an antipsychotic drug approved for the treatment of schizophrenia in several countries including the United States. In animal studies in mice, loxapine reduced neuropathic pain. Hence, in a proof-of-principle and dose-escalating study the tolerability and analgesic efficacy of loxapine will be evaluated in patients with neuropathic pain. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOXAPINE SUCCINATE
Condition Name
Clinical Trial Locations for LOXAPINE SUCCINATE
Trials by Country
Clinical Trial Progress for LOXAPINE SUCCINATE
Clinical Trial Phase
Clinical Trial Sponsors for LOXAPINE SUCCINATE
Sponsor Name